Associated Papers
Insights Into Genetic Variations of the OCT1 Gene in Metformin Poor Responders Among Bangladeshi Type 2 Diabetic Patients.
Begum R et al.
Advances in Pharmacological and Pharmaceutical Sciences, 2025
The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.
Yee SW et al.
Molecular Cell, 2024
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.
Yee SW et al.
Biorxiv : the Preprint Server for Biology, 2023
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.
Nies AT et al.
Pharmacology & Therapeutics, 2022
Expansion of Knowledge on OCT1 Variant Activity In Vitro and In Vivo Using Oct1/2-/- Mice.
Morse BL et al.
Frontiers in Pharmacology, 2021
Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport.
Jensen O et al.
Frontiers in Pharmacology, 2021
Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.
Matthaei J et al.
Frontiers in Pharmacology, 2021
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.
Cabral LKD et al.
Cancers, 2020
Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans.
Jensen O et al.
Clinical Pharmacology and Therapeutics, 2020
Diffusion Mechanism Modeling of Metformin in Human Organic Cationic Amino Acid Transporter one and Functional Impact of S189L, R206C, and G401S Mutation.
Cano L et al.
Frontiers in Pharmacology, 2020
The genetic landscape of the human solute carrier (SLC) transporter superfamily.
Schaller L et al.
Human Genetics, 2019
Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A.
Rafehi M et al.
Frontiers in Pharmacology, 2019
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP et al.
Medicine, 2018
Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency.
Tzvetkov MV et al.
Clinical Pharmacology and Therapeutics, 2018
Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
Meyer MJ et al.
Plos One, 2017
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins.
Molnár J et al.
Plos One, 2016
Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.
Arimany-Nardi C et al.
Frontiers in Pharmacology, 2016
Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells.
Arimany-Nardi C et al.
The Pharmacogenomics Journal, 2015
Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers.
Christensen MMH et al.
European Journal of Clinical Pharmacology, 2015
Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa.
Du Plessis M et al.
Molecular Biology Reports, 2015
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.
Seitz T et al.
Genome Medicine, 2015
Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa.
Jacobs C et al.
Genetics and Molecular Biology, 2014
A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin.
Christensen MM et al.
Pharmacogenetics and Genomics, 2013
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E et al.
Hepatology (baltimore, Md.), 2013
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.
Lozano E et al.
Biomed Research International, 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
Chen L et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Nies AT et al.
Hepatology (baltimore, Md.), 2009
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.
Avery P et al.
Pharmacogenomics and Personalized Medicine, 2009
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Shu Y et al.
Clinical Pharmacology and Therapeutics, 2008
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.
Shu Y et al.
Proceedings of the National Academy of Sciences of the United States of America, 2003